Book
Book
Histopathology, ISSN 0309-0167, 04/2019, Volume 74, Issue 5, pp. 676 - 687
Endometrial hyperplasia (EH) is classified into benign and precancerous according to two different histomorphological systems: the World Health Organisation...
endometrial precancer | World Health Organization | concurrent cancer | prognosis | endometrial intraepithelial neoplasia | endometrioid adenocarcinoma | DIAGNOSIS | MANAGEMENT | INTRAEPITHELIAL-NEOPLASIA CLASSIFICATION | CURETTAGE | PATHOLOGY | REPRODUCIBILITY | PREDICTION | CELL BIOLOGY | WOMEN | ATYPIA | CARCINOMA | Oncology, Experimental | Hyperplasia | Medical societies | Research | Health aspects | Risk factors | Cancer | Databases | Hysterectomy | Endometrium
endometrial precancer | World Health Organization | concurrent cancer | prognosis | endometrial intraepithelial neoplasia | endometrioid adenocarcinoma | DIAGNOSIS | MANAGEMENT | INTRAEPITHELIAL-NEOPLASIA CLASSIFICATION | CURETTAGE | PATHOLOGY | REPRODUCIBILITY | PREDICTION | CELL BIOLOGY | WOMEN | ATYPIA | CARCINOMA | Oncology, Experimental | Hyperplasia | Medical societies | Research | Health aspects | Risk factors | Cancer | Databases | Hysterectomy | Endometrium
Journal Article
Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, 03/2019, Volume 98, Issue 3, pp. 275 - 286
Introduction Endometrial hyperplasia may be either a benign proliferation or a premalignant lesion. In order to differentiate these two conditions, two...
atypical endometrial hyperplasia | endometrioid adenocarcinoma | phosphatase and tensin homolog | cancer precursor | endometrial hyperplasia without atypia | biomarker | endometrial intraepithelial neoplasia | IMMUNOHISTOCHEMICAL EXPRESSION | ADENOCARCINOMA | RECEPTOR | INTRAEPITHELIAL NEOPLASIA | BETA-CATENIN | CANCER | OBSTETRICS & GYNECOLOGY | ATYPICAL HYPERPLASIA | CARCINOMA | BIOPSIES | PROGRESSION | Immunohistochemistry | Analysis | Phosphatases
atypical endometrial hyperplasia | endometrioid adenocarcinoma | phosphatase and tensin homolog | cancer precursor | endometrial hyperplasia without atypia | biomarker | endometrial intraepithelial neoplasia | IMMUNOHISTOCHEMICAL EXPRESSION | ADENOCARCINOMA | RECEPTOR | INTRAEPITHELIAL NEOPLASIA | BETA-CATENIN | CANCER | OBSTETRICS & GYNECOLOGY | ATYPICAL HYPERPLASIA | CARCINOMA | BIOPSIES | PROGRESSION | Immunohistochemistry | Analysis | Phosphatases
Journal Article
Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, 08/2019, Volume 98, Issue 8, pp. 976 - 987
Introduction Progestins are used as conservative treatment of endometrial hyperplasia (EH) and early endometrial cancer (EEC). We aimed to assess whether...
hormonal therapy | progestin | endometrial hyperplasia | estrogen receptor | predictive markers | endometrial cancer | progesterone receptor | endometrial intraepithelial neoplasia | levonorgestrel‐intrauterine device | levonorgestrel-intrauterine device | REGRESSION | LEVONORGESTREL | COMPLEX ATYPICAL HYPERPLASIA | PROGNOSTIC-FACTORS | ADENOCARCINOMA | MEDROXYPROGESTERONE ACETATE | LNG-IUS | OBSTETRICS & GYNECOLOGY | EXPRESSIONS | THERAPY | YOUNG-WOMEN | Contraceptive drug implants | Medical research | Endometrial cancer | Analysis | Hyperplasia | Estrogen | Levonorgestrel | Medicine, Experimental | Phenols | Progesterone | Cancer
hormonal therapy | progestin | endometrial hyperplasia | estrogen receptor | predictive markers | endometrial cancer | progesterone receptor | endometrial intraepithelial neoplasia | levonorgestrel‐intrauterine device | levonorgestrel-intrauterine device | REGRESSION | LEVONORGESTREL | COMPLEX ATYPICAL HYPERPLASIA | PROGNOSTIC-FACTORS | ADENOCARCINOMA | MEDROXYPROGESTERONE ACETATE | LNG-IUS | OBSTETRICS & GYNECOLOGY | EXPRESSIONS | THERAPY | YOUNG-WOMEN | Contraceptive drug implants | Medical research | Endometrial cancer | Analysis | Hyperplasia | Estrogen | Levonorgestrel | Medicine, Experimental | Phenols | Progesterone | Cancer
Journal Article
Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, 03/2019, Volume 98, Issue 3, pp. 287 - 299
Introduction Benign and precancerous endometrial hyperplasias (EH) are differentiated according to two alternative histomorphologic classifications: World...
paired box 2 protein | cancer precursor | biomarker | endometrial hyperplasia | endometrial intraepithelial neoplasia | endometrioid adenocarcinoma | MARKER | PTEN | CANCER | OBSTETRICS & GYNECOLOGY | ROLES | GENES | GROWTH | PROGRESSION | Immunohistochemistry | Diagnosis | Endometrial cancer | Carcinogenesis | Analysis | Hyperplasia
paired box 2 protein | cancer precursor | biomarker | endometrial hyperplasia | endometrial intraepithelial neoplasia | endometrioid adenocarcinoma | MARKER | PTEN | CANCER | OBSTETRICS & GYNECOLOGY | ROLES | GENES | GROWTH | PROGRESSION | Immunohistochemistry | Diagnosis | Endometrial cancer | Carcinogenesis | Analysis | Hyperplasia
Journal Article
Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, 07/2019, Volume 98, Issue 7, pp. 842 - 855
Introduction Atypical polypoid adenomyoma is an uncommon uterine lesion which can coexist with endometrial atypical hyperplasia and/or cancer. Atypical...
endometrium | progestin | conservative treatment | atypical polypoid adenomyofibroma | hysteroscopy | transcervical resection | OUTCOMES | HYPERPLASIA | OBSTETRICS & GYNECOLOGY | Women | Medical research | Endometrial cancer | Analysis | Menopause | Medicine, Experimental | Development and progression | Health aspects
endometrium | progestin | conservative treatment | atypical polypoid adenomyofibroma | hysteroscopy | transcervical resection | OUTCOMES | HYPERPLASIA | OBSTETRICS & GYNECOLOGY | Women | Medical research | Endometrial cancer | Analysis | Menopause | Medicine, Experimental | Development and progression | Health aspects
Journal Article
Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, 09/2019, Volume 98, Issue 9, pp. 1086 - 1099
Introduction Progestogens are widely used for the conservative treatment of endometrial hyperplasia and early endometrial cancer. Nevertheless, they do not...
progestin | endometrial hyperplasia | endometrioid adenocarcinoma | endometrial cancer | immunohistochemical marker | Progestogens | endometrial intraepithelial neoplasia | THERAPY RESPONSE | LEVONORGESTREL | COMPLEX ATYPICAL HYPERPLASIA | PROGNOSTIC-FACTORS | ADENOCARCINOMA | MEDROXYPROGESTERONE ACETATE | LNG-IUS | OBSTETRICS & GYNECOLOGY | PROGESTERONE-RECEPTOR | YOUNG-WOMEN | EXPRESSION | Care and treatment | Endometrial cancer | Analysis | Oncology, Experimental | Hyperplasia | Estrogen | Progesterone | Research | Cancer
progestin | endometrial hyperplasia | endometrioid adenocarcinoma | endometrial cancer | immunohistochemical marker | Progestogens | endometrial intraepithelial neoplasia | THERAPY RESPONSE | LEVONORGESTREL | COMPLEX ATYPICAL HYPERPLASIA | PROGNOSTIC-FACTORS | ADENOCARCINOMA | MEDROXYPROGESTERONE ACETATE | LNG-IUS | OBSTETRICS & GYNECOLOGY | PROGESTERONE-RECEPTOR | YOUNG-WOMEN | EXPRESSION | Care and treatment | Endometrial cancer | Analysis | Oncology, Experimental | Hyperplasia | Estrogen | Progesterone | Research | Cancer
Journal Article
APMIS, ISSN 0903-4641, 06/2019, Volume 127, Issue 6, pp. 427 - 434
The 2014 World Health Organization (WHO) classification of endometrial hyperplasia (EH) defines premalignant EH based on only cytologic atypia, disregarding...
endometrial precancer | World Health Organization | atypical endometrial hyperplasia | endometrial intraepithelial neoplasia | endometrioid adenocarcinoma | LONG-TERM | INTRAEPITHELIAL-NEOPLASIA CLASSIFICATION | RISK | MICROBIOLOGY | IMMUNOLOGY | PATHOLOGY | CANCER | PREDICTION | CARCINOMA | Bias | Endometrial Neoplasms - classification | Humans | Precancerous Conditions - classification | Female | Endometrial Hyperplasia - pathology | Endometrial Hyperplasia - therapy | Endometrial Hyperplasia - classification | Development and progression | Research | Oncology, Experimental | Analysis | Hyperplasia | Cancer | Architecture | Classification | Health risks | Risk | Endometrium | Complexity
endometrial precancer | World Health Organization | atypical endometrial hyperplasia | endometrial intraepithelial neoplasia | endometrioid adenocarcinoma | LONG-TERM | INTRAEPITHELIAL-NEOPLASIA CLASSIFICATION | RISK | MICROBIOLOGY | IMMUNOLOGY | PATHOLOGY | CANCER | PREDICTION | CARCINOMA | Bias | Endometrial Neoplasms - classification | Humans | Precancerous Conditions - classification | Female | Endometrial Hyperplasia - pathology | Endometrial Hyperplasia - therapy | Endometrial Hyperplasia - classification | Development and progression | Research | Oncology, Experimental | Analysis | Hyperplasia | Cancer | Architecture | Classification | Health risks | Risk | Endometrium | Complexity
Journal Article
APMIS, ISSN 0903-4641, 04/2019, Volume 127, Issue 4, pp. 161 - 169
Guidelines recommend protein phosphatase and tensin homolog (PTEN) immunohistochemistry for differentiating between benign endometrial hyperplasia (BEH) and...
endometrial hyperplasia without atypia | cancer precursor | biomarker | Atypical endometrial hyperplasia | endometrial intraepithelial neoplasia | endometrioid adenocarcinoma | MARKER | RISK | MICROBIOLOGY | PROGESTERONE-RECEPTOR EXPRESSION | IMMUNOLOGY | PATHOLOGY | INTRAEPITHELIAL NEOPLASIA | BETA-CATENIN | CANCER | ESTROGEN | CARCINOMA | BIOPSIES | PROGRESSION | Immunohistochemistry | Phosphatases | Diagnosis | Analysis | Hyperplasia | Proteins | Tensin | Accuracy | Homology | Diagnostic systems | Protein phosphatase | Criteria | PTEN protein | Endometrium
endometrial hyperplasia without atypia | cancer precursor | biomarker | Atypical endometrial hyperplasia | endometrial intraepithelial neoplasia | endometrioid adenocarcinoma | MARKER | RISK | MICROBIOLOGY | PROGESTERONE-RECEPTOR EXPRESSION | IMMUNOLOGY | PATHOLOGY | INTRAEPITHELIAL NEOPLASIA | BETA-CATENIN | CANCER | ESTROGEN | CARCINOMA | BIOPSIES | PROGRESSION | Immunohistochemistry | Phosphatases | Diagnosis | Analysis | Hyperplasia | Proteins | Tensin | Accuracy | Homology | Diagnostic systems | Protein phosphatase | Criteria | PTEN protein | Endometrium
Journal Article
APMIS, ISSN 0903-4641, 11/2019, Volume 127, Issue 11, pp. 699 - 709
We aimed to assess (1)‐whether nuclear β‐catenin is a marker of endometrial precancer, and (2)‐the diagnostic accuracy of β‐catenin immunohistochemistry in the...
endometrial precancer | endometrial hyperplasia without atypia | Atypical endometrial hyperplasia | endometrial intraepithelial neoplasia | Immunohistochemistry | Accuracy | Sensitivity | Hyperplasia | Markers | Benign | Diagnostic systems | Differential diagnosis | Diagnosis | Catenin | Endometrium | Subgroups
endometrial precancer | endometrial hyperplasia without atypia | Atypical endometrial hyperplasia | endometrial intraepithelial neoplasia | Immunohistochemistry | Accuracy | Sensitivity | Hyperplasia | Markers | Benign | Diagnostic systems | Differential diagnosis | Diagnosis | Catenin | Endometrium | Subgroups
Journal Article
APMIS, ISSN 0903-4641, 09/2019, Volume 127, Issue 9, pp. 597 - 606
AT‐rich interaction domain 1A (ARID1A) is a tumor suppressor protein involved in endometrioid carcinogenesis. The expression of ARID1A may be lost in the...
cancer risk | endometrial hyperplasia | endometrial intraepithelial neoplasia | AT‐rich interaction domain 1A | AT-rich interaction domain 1A | PTEN | RISK | MICROBIOLOGY | IMMUNOLOGY | PATHOLOGY | INTRAEPITHELIAL NEOPLASIA | EXPRESSION | Prognosis | Diagnosis | Analysis | Hyperplasia | Cancer | Immunohistochemistry | Sensitivity | Accuracy | Carcinogens | Sensitivity analysis | Health risks | Tumor suppressor genes | Diagnostic systems | Carcinogenesis | Endometrium
cancer risk | endometrial hyperplasia | endometrial intraepithelial neoplasia | AT‐rich interaction domain 1A | AT-rich interaction domain 1A | PTEN | RISK | MICROBIOLOGY | IMMUNOLOGY | PATHOLOGY | INTRAEPITHELIAL NEOPLASIA | EXPRESSION | Prognosis | Diagnosis | Analysis | Hyperplasia | Cancer | Immunohistochemistry | Sensitivity | Accuracy | Carcinogens | Sensitivity analysis | Health risks | Tumor suppressor genes | Diagnostic systems | Carcinogenesis | Endometrium
Journal Article
Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, 12/2018, Volume 97, Issue 12, pp. 1415 - 1426
Introduction Endometrial hyperplasia is differentiated into benign or premalignant. Two histological classifications are used for this purpose: World Health...
apoptosis | cancer | biomarker | endometrial hyperplasia | neoplasia
apoptosis | cancer | biomarker | endometrial hyperplasia | neoplasia
Journal Article
Archives of Gynecology and Obstetrics, ISSN 0932-0067, 5/2019, Volume 299, Issue 5, pp. 1233 - 1242
Benign and precancerous endometrial hyperplasias (EH) are differentiated thorough two possible histomorphologic classifications: WHO (adopting the subjective...
Obstetrics/Perinatology/Midwifery | Human Genetics | World Health Organization | Prognosis | Medicine & Public Health | Endometrial intraepithelial neoplasia | Gynecology | Endometroid adenocarcinoma | Concurrent cancer | Endometrial precancer | Endocrinology | LONG-TERM | DIAGNOSIS | COMPLEX | INTRAEPITHELIAL-NEOPLASIA CLASSIFICATION | MARKER | EIN | REPRODUCIBILITY | PTEN EXPRESSION | PREDICTION | OBSTETRICS & GYNECOLOGY | CARCINOMA | Development and progression | Research | Oncology, Experimental | Cancer
Obstetrics/Perinatology/Midwifery | Human Genetics | World Health Organization | Prognosis | Medicine & Public Health | Endometrial intraepithelial neoplasia | Gynecology | Endometroid adenocarcinoma | Concurrent cancer | Endometrial precancer | Endocrinology | LONG-TERM | DIAGNOSIS | COMPLEX | INTRAEPITHELIAL-NEOPLASIA CLASSIFICATION | MARKER | EIN | REPRODUCIBILITY | PTEN EXPRESSION | PREDICTION | OBSTETRICS & GYNECOLOGY | CARCINOMA | Development and progression | Research | Oncology, Experimental | Cancer
Journal Article
Archives of Gynecology and Obstetrics, ISSN 0932-0067, 6/2019, Volume 299, Issue 6, pp. 1511 - 1524
Rates of progression of endometrial hyperplasia (EH) to endometrial cancer (EC) are highly variable. Among several prognostic markers, PTEN has been...
Obstetrics/Perinatology/Midwifery | Human Genetics | Tumor suppressor protein phosphatase | Immunohistochemical | Prognosis | Medicine & Public Health | Endometrial intraepithelial neoplasia | Endometrioid adenocarcinoma | Gynecology | EIN | Tensin homolog | Endocrinology | COMPLEX | MARKER | OBSTETRICS & GYNECOLOGY | CARCINOMA | BIOPSIES | PROGRESSION | INTRAEPITHELIAL-NEOPLASIA | Immunohistochemistry | Phosphatases | Endometrial cancer | Hyperplasia | Hysterectomy | Health aspects | Risk factors | Cancer
Obstetrics/Perinatology/Midwifery | Human Genetics | Tumor suppressor protein phosphatase | Immunohistochemical | Prognosis | Medicine & Public Health | Endometrial intraepithelial neoplasia | Endometrioid adenocarcinoma | Gynecology | EIN | Tensin homolog | Endocrinology | COMPLEX | MARKER | OBSTETRICS & GYNECOLOGY | CARCINOMA | BIOPSIES | PROGRESSION | INTRAEPITHELIAL-NEOPLASIA | Immunohistochemistry | Phosphatases | Endometrial cancer | Hyperplasia | Hysterectomy | Health aspects | Risk factors | Cancer
Journal Article
BMC WOMENS HEALTH, ISSN 1472-6874, 10/2018, Volume 18, Issue 1, pp. 169 - 5
BackgroundMorcellation of undiagnosed uterine sarcoma is cause of abdominal/pelvic dissemination, residual tumor and recurrence. In the preoperative evaluation...
Leiomyoma | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | Choice of therapy | Minimally-invasive surgical treatments | Serum markers | Surgical approach | Occult malignancy | Fibroid | Menorrhagia | LDH isoforms | OBSTETRICS & GYNECOLOGY | Uterine diseases | Lactate dehydrogenase | Usage | Diagnosis | Research | Magnetic resonance imaging
Leiomyoma | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | Choice of therapy | Minimally-invasive surgical treatments | Serum markers | Surgical approach | Occult malignancy | Fibroid | Menorrhagia | LDH isoforms | OBSTETRICS & GYNECOLOGY | Uterine diseases | Lactate dehydrogenase | Usage | Diagnosis | Research | Magnetic resonance imaging
Journal Article